Hospital Pharmacy Europe - Specials and orphan drugs,

Click here

Thursday 23 May 2013 Register Login

You are here:

Suppliers Guide

New neurology product

Hospital Pharmacy Europe is assisting with a survey on messaging for a new neurology product. Click here

LATEST ISSUE

Contamination control and preparation of anticancer drugs, medicines reconciliation, Ruconest drug evaluation, ivacaftor for cystic fibrosis , oxycodone-naloxone prolonged-release tablets, IV chemotherapy, capsaicin in the treatment of severe neuropathic pain, alitretinoin in severe chronic hand eczema, Zyclara for actinic keratoses

Pharmacy Zone: Specials and orphan drugs

Magazine	Sponsored content
News	Video

Page:

1

Thu 8 Nov
2012

Albireo granted orphan drug designation for A4250
Albireo AB (Gothenburg, Sweden; “Albireo”), a biopharmaceutical company specialising in gastroenterology, today...

Wed 17 Oct
2012

Issues affecting access to orphan drugs in Europe
Because they often are the only available option to treat a disease, some orphan drugs are considered to have high value and, as...

Tue 24 Jul
2012

Market access of orphan drugs: one size fits all?
The European Union has introduced measures to stimulate the development of orphan drugs, and many Member States have in place...

Tue 17 Jan
2012

Orphan drug committee proposes new designations
A total of 16 recommendations were submitted at the first meeting of the year

Fri 4 Nov
2011

New drug target 'can stop debilitating MS'
Physical disability associated with multiple sclerosis may be preventable, study finds

Mon 10 Oct
2011

SMC rules against funding breast cancer drug
Opposition from Cancer Foundation as Scottish women denied life-prolonging treatment

Fri 7 Oct
2011

Cost of orphan drugs to EU 'sustainable until 2020'
Ten-year forecast suggests rare disease expenditure will fall within EU budget

Thu 6 Oct
2011

CHMP recommends Xarelto® for DVT and stroke prevention
Bayer’s Xarelto® (rivaroxaban) recommended by CHMP for EU approval

Tue 4 Oct
2011

Oral antibiotic launched for travellers' diarrhoea
UK Licence granted for Xifaxanta™ (rifaxamin) to treat non-invasive travellers’ diarrhoea

Fri 30 Sep
2011

EMCC: BIBF 1120 'as effective as bevacizumab' for colorectal cancer
First-line treatment with inhibitor also produces less serious adverse events

Fri 30 Sep
2011

ERS: New drug 'significantly increases lung function in COPD'
NVA237 'provides superior bronchodilation and exercise endurance than placebo'

Thu 29 Sep
2011

EMCC: Everolimus and exemestane 'improve breast cancer survival rate'
New hope for advanced post-menopausal breast cancer patients resistant to hormonal therapy

Wed 28 Sep
2011

ERS: Moxifloxacin 'demostrates non-inferiority for COPD'
Drug associated with significantly lower failure rates than gold-standard, congress told

Wed 28 Sep
2011

ERS: Imatinib 'significantly improves walking distance'
Walking distance 'significantly increased' in pulmonary arterial hypertension patients

Tue 27 Sep
2011

EMCC: Afinitor® 'more than doubles breast cancer survival'
Everolimus combined with hormonal therapy 'reduces risk of progression by 57%'

Tue 27 Sep
2011

Afinitor® 'effective in angiomyolipoma treatment'
Drug recorded 42% response rate in treatment of tumours associated with tuberous sclerosis

Mon 26 Sep
2011

EMA recommends Rasitrio® for high blood pressure
Matter referred to the European Commission and final decision expected in three months

Mon 26 Sep
2011

EMA recommends Edurant® for HIV-1 approval
Edurant® (rilpivirine) receives positive opinion for treatment-naive adults with HIV-1

Thu 22 Sep
2011

Tyrosine kinase inhibitor 'reduces IPF lung decline'
Phase II trial with BIBF 1120 shows efficacy for idiopathic pulmonary fibrosis patients

Thu 22 Sep
2011

European Commission authorise sedative Dexdor®
Dexmedetomidine licensed in intensive care units in all 27 countries of European Union

Page:

1

Web design, hosting and programming by ModeZero